Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03665129
Title IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001)
Acronym STELLAR-001
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Innate Pharma
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | FRA

Additional content available in CKB BOOST